Highlights
- ParagonCare has received a Strongbuy consensus rating with an average target price of AUD 0.50.
- Bell Potter Securities has issued a buy rating with a target price of AUD 0.49.
- Investor sentiment might have strengthened as the company progresses two strategic acquisitions in Asia.
Paragon Care Limited (ASX:PGC) has attracted significant analyst support, securing a Strongbuy consensus rating according to EODHD/Others data, accompanied by a consensus target price of AUD 0.50. The positive sentiment has been reinforced by Bell Potter Securities (Institutional), which recently issued a buy rating on the stock with a target price of AUD 0.49.
ParagonCare continues to strengthen its position within the Asia-Pacific healthcare sector. Market observers are closely tracking the company’s expansion strategy, which in recent months has been marked by two major acquisition agreements designed to broaden its reach across key Asian healthcare markets.
Advancing Regional Growth Through Asian Expansion
On 1 December 2025, ParagonCare announced it had entered into a binding agreement to acquire PT Haju Medical Indonesia and Insightof Co., Ltd. The acquisition, valued at AUD 70 million, will be executed through a combination of an upfront payment of AUD 30 million upon completion and a deferred balance payable over approximately two years.
Haju Medical, a leading provider of medical aesthetic technology and services in Indonesia, currently employs more than 100 staff and has established a presence by supporting clinics and dealers with South Korean-led medical expertise. For the financial year ending 31 December 2024, Haju reported AUD 30 million in revenue and AUD 7.7 million in EBITDA.
The acquisition, expected to be completed by 30 January 2026, will be funded using ParagonCare’s previously secured working capital facilities in New Zealand and Thailand, in addition to existing surplus cash within the group.
This strategic move extends ParagonCare’s footprint across the Asia-Pacific aesthetics market, complementing its operations in Thailand and emerging platforms in Australia, New Zealand, the Philippines, Vietnam and Japan.
Somnotec Acquisition Strengthens MedTech Capabilities
The Haju deal follows ParagonCare’s announcement on 28 October 2025 of its intention to acquire the Somnotec Group, a Southeast Asia-based distributor of medical devices and technology.
The agreement, based on an enterprise value of SGD 24 million (approximately AUD 28.4 million), includes AUD 18 million payable upfront and the remainder over two years. Somnotec, founded in 2003 and headquartered in Singapore, reported AUD 40 million in revenue and AUD 5.6 million in EBITDA for the year ending 31 December 2024.
Somnotec’s operations span Singapore, Malaysia, Indonesia, Thailand and the Philippines, offering ParagonCare greater scale across its MedTech and Contract Logistics channels. Completion is expected by 15 December 2025, subject to regulatory and operational approvals.
Outlook Aligned With Analyst Ratings
With two significant acquisitions in progress and expanding regional operations, ParagonCare continues to draw favourable attention from analysts.






Please wait processing your request...